Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride
OPEN PeerJ | 16 Mar 2017
T Kiguradze, WH Temps, PR Yarnold, J Cashy, RE Brannigan, B Nardone, G Micali, DP West and SM Belknap
Case reports describe persistent erectile dysfunction (PED) associated with exposure to 5α-reductase inhibitors (5α-RIs). Clinical trial reports and the manufacturers' full prescribing information (FPI) for finasteride and dutasteride state that risk of sexual adverse effects is not increased by longer duration of 5α-RI exposure and that sexual adverse effects of 5α-RIs resolve in men who discontinue exposure.
* Data courtesy of Altmetric.com